From CNBC:

Shares of Viking Therapeutics surged over 120% as their weight loss drug, VK2735, showed promising results in a mid-stage trial. Patients saw weight loss of up to 14.7% after 13 weeks, with 88% achieving at least 10% weight loss. The drug demonstrated safety and tolerability, with gastrointestinal side effects like nausea and vomiting.

Analysts expect the weight loss drug industry to reach $100 billion by the end of the decade. Viking Therapeutics could potentially partner with or be acquired by larger pharmaceutical companies like Pfizer. The company plans to present full Phase 2 data and discuss further development with the FDA. Early stage trial data on an oral version is also expected.

Viking Therapeutics’ successful trial results suggest potential competition in the weight loss drug market, challenging Novo Nordisk and Eli Lilly. However, manufacturing at scale remains a challenge, giving Novo Nordisk and Eli Lilly a competitive advantage. Analysts believe Viking Therapeutics’ drug could expand the market beyond the current duopoly.



Read more at CNBC: Viking Therapeutics weight loss drug shows promising trial results